<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Inhibiting Human Cytomegalovirus by Targeting Major Immediate-Early Gene Expression or" exact="Protein" post="Function https://orcid.org/0000-0001-7673-5212AdamsonCatherine S.*https://orcid.org/0000-0002-7115-407XNevelsMichael M.*[], *Correspondence: csa21@st-andrews.ac.uk (C.S.A.); mmn3@st-andrews.ac.uk (M.M.N.)"/>
 <result pre="cytomegalovirus (HCMV), one of eight human herpesviruses, establishes lifelong latent" exact="infections" post="in most people worldwide. Primary or reactivated HCMV infections"/>
 <result pre="human herpesviruses, establishes lifelong latent infections in most people worldwide." exact="Primary" post="or reactivated HCMV infections cause severe disease in immunosuppressed"/>
 <result pre="latent infections in most people worldwide. Primary or reactivated HCMV" exact="infections" post="cause severe disease in immunosuppressed patients and congenital defects"/>
 <result pre="most people worldwide. Primary or reactivated HCMV infections cause severe" exact="disease" post="in immunosuppressed patients and congenital defects in children. There"/>
 <result pre="reactivated HCMV infections cause severe disease in immunosuppressed patients and" exact="congenital" post="defects in children. There is no vaccine for HCMV,"/>
 <result pre="Most approved HCMV antivirals target late molecular processes in the" exact="viral" post="replication cycle including DNA replication and packaging. &quot;Bright and"/>
 <result pre="DNA replication and packaging. &quot;Bright and early&quot; events in HCMV" exact="infection" post="have not been exploited for systemic prevention or treatment"/>
 <result pre="early&quot; events in HCMV infection have not been exploited for" exact="systemic" post="prevention or treatment of disease. Initiation of HCMV replication"/>
 <result pre="disease. Initiation of HCMV replication depends on transcription from the" exact="viral" post="major immediate-early (IE) gene. Alternative transcripts produced from this"/>
 <result pre="gene give rise to the IE1 and IE2 families of" exact="viral" post="proteins, which localize to the host cell nucleus. The"/>
 <result pre="a member of the Betaherpesvirinae, a subfamily of the Herpesviridae." exact="Infectious" post="HCMV particles are composed of a polymorphic lipid envelope"/>
 <result pre="HCMV particles are composed of a polymorphic lipid envelope containing" exact="viral" post="glycoproteins, a tegument layer consisting mainly of viral phosphoproteins"/>
 <result pre="envelope containing viral glycoproteins, a tegument layer consisting mainly of" exact="viral" post="phosphoproteins and an icosahedral protein capsid encasing the viral"/>
 <result pre="of viral phosphoproteins and an icosahedral protein capsid encasing the" exact="viral" post="genome [1,2]. The HCMV genome comprises roughly 235,000 base"/>
 <result pre="a single chromosome. By harnessing cellular RNA polymerase II, the" exact="viral" post="genome gives rise to a highly complex transcriptome encompassing"/>
 <result pre="open reading frames as well as non-coding RNAs [3,4,5,6,7,8,9]. Upon" exact="infection" post="of permissive cells, the HCMV genome is expressed and"/>
 <result pre="steps referred to as immediate-early (IE), early and late. The" exact="viral" post="major IE gene, expressed within hours of infection, and"/>
 <result pre="intrinsic and innate host cell responses and initiate transcription from" exact="viral" post="early genes [10,11,12,13,14,15]. Early gene products regulate host cell"/>
 <result pre="to facilitate virus replication and contribute to late events including" exact="viral" post="DNA replication and packaging. Typical early viral proteins include"/>
 <result pre="late events including viral DNA replication and packaging. Typical early" exact="viral" post="proteins include the DNA polymerase (pUL54), phosphotransferase (pUL97) and"/>
 <result pre="approved anti-HCMV drugs [16,17,18]. Finally, late genes are expressed after" exact="viral" post="DNA replication has commenced and encode mostly structural proteins"/>
 <result pre="types of poorly differentiated cells including myeloid progenitors for latent" exact="infection" post="with limited viral gene expression [22,23,24,25,26]. Viral reactivation from"/>
 <result pre="poorly differentiated cells including myeloid progenitors for latent infection with" exact="limited" post="viral gene expression [22,23,24,25,26]. Viral reactivation from latency is"/>
 <result pre="differentiated cells including myeloid progenitors for latent infection with limited" exact="viral" post="gene expression [22,23,24,25,26]. Viral reactivation from latency is brought"/>
 <result pre="progenitors for latent infection with limited viral gene expression [22,23,24,25,26]." exact="Viral" post="reactivation from latency is brought about by cellular differentiation"/>
 <result pre="of years has resulted in latent or low-level productive HCMV" exact="infection" post="that persists for the life of the host in"/>
 <result pre="that persists for the life of the host in the" exact="absence of" post="major disease symptoms. This type of persistence is due"/>
 <result pre="the life of the host in the absence of major" exact="disease" post="symptoms. This type of persistence is due to a"/>
 <result pre="between our intrinsic, innate and adaptive immune responses and manifold" exact="viral" post="countermeasures. Developmental or acquired immune system defects disrupt the"/>
 <result pre="intrinsic, innate and adaptive immune responses and manifold viral countermeasures." exact="Developmental" post="or acquired immune system defects disrupt the delicate balance"/>
 <result pre="and adaptive immune responses and manifold viral countermeasures. Developmental or" exact="acquired" post="immune system defects disrupt the delicate balance between virus"/>
 <result pre="balance between virus and host and can result in severe" exact="disease" post="outcomes. HCMV infection is the most common congenital (present"/>
 <result pre="and host and can result in severe disease outcomes. HCMV" exact="infection" post="is the most common congenital (present at birth) infection"/>
 <result pre="in severe disease outcomes. HCMV infection is the most common" exact="congenital" post="(present at birth) infection worldwide, with an estimated incidence"/>
 <result pre="HCMV infection is the most common congenital (present at birth)" exact="infection" post="worldwide, with an estimated incidence in developed countries between"/>
 <result pre="incidence results in approximately 60,000 neonates born every year with" exact="congenital" post="HCMV infection in the United States and the European"/>
 <result pre="in approximately 60,000 neonates born every year with congenital HCMV" exact="infection" post="in the United States and the European Union combined"/>
 <result pre="the United States and the European Union combined [30,31,32,33]. Since" exact="congenital" post="HCMV infection parallels maternal seroprevalence, the estimated incidence in"/>
 <result pre="States and the European Union combined [30,31,32,33]. Since congenital HCMV" exact="infection" post="parallels maternal seroprevalence, the estimated incidence in developing countries"/>
 <result pre="and other disorders present at birth or long-term sequelae including" exact="hearing loss." post="Consequently, HCMV has been recognized as a leading cause"/>
 <result pre="leading cause of birth defects. HCMV reactivation from latency or" exact="primary" post="infection also remain a major source of morbidity and"/>
 <result pre="cause of birth defects. HCMV reactivation from latency or primary" exact="infection" post="also remain a major source of morbidity and mortality"/>
 <result pre="of solid organ and haematopoietic stem cell allografts, people with" exact="acquired" post="immunodeficiency syndrome (AIDS) and other critically ill patients. For"/>
 <result pre="solid organ and haematopoietic stem cell allografts, people with acquired" exact="immunodeficiency" post="syndrome (AIDS) and other critically ill patients. For example,"/>
 <result pre="organ and haematopoietic stem cell allografts, people with acquired immunodeficiency" exact="syndrome" post="(AIDS) and other critically ill patients. For example, HCMV"/>
 <result pre="syndrome (AIDS) and other critically ill patients. For example, HCMV" exact="infections" post="are diagnosed in roughly 50% of all allograft recipients"/>
 <result pre="[36,37,38]. Cytomegaloviruses are highly species-specific, but certain aspects of HCMV" exact="infection" post="and pathogenesis are replicated in animal models including mice"/>
 <result pre="various routes including sexual contact, organ and stem cell transplantation," exact="breast" post="milk and from mother to baby (transplacental) during pregnancy."/>
 <result pre="improve the adaptive immune response and reduce the risk of" exact="congenital" post="infection. However, the value of this treatment is controversial"/>
 <result pre="infection. However, the value of this treatment is controversial with" exact="limited" post="data supporting improved clinical outcomes [45,46,47,48,49]. The development of"/>
 <result pre="enzyme’s active site, thus preventing nucleotide incorporation into the elongating" exact="viral" post="DNA [60,64]. A closely related nucleoside analogue, Acyclovir, is"/>
 <result pre="disease. However, GCV is associated with serious toxicity including neutropenia," exact="thrombocytopenia" post="or anaemia [66,67]. In addition, the development of GCV-resistant"/>
 <result pre="GCV is associated with serious toxicity including neutropenia, thrombocytopenia or" exact="anaemia" post="[66,67]. In addition, the development of GCV-resistant HCMV strains"/>
 <result pre="with prolonged exposure, severe immunosuppression, suboptimal GCV doses and high" exact="viral" post="loads poses a serious challenge. In 90% of all"/>
 <result pre="competitive incorporation into the elongating DNA chain by pUL54 inhibits" exact="viral" post="genome replication. Resistance to Foscarnet and Cidofovir occurs with"/>
 <result pre="the elongating DNA chain by pUL54 inhibits viral genome replication." exact="Resistance" post="to Foscarnet and Cidofovir occurs with rates similar to"/>
 <result pre="bioavailability as well as serious side effects including nephrotoxicity have" exact="limited" post="their clinical use [66,67]. Brincidofovir is a lipid ester"/>
 <result pre="of molecules have been discovered that inhibit the packaging of" exact="viral" post="DNA into preformed capsids by the HCMV terminase complex."/>
 <result pre="of HCMV DNA in stem cell transplant patients in the" exact="absence of" post="myelotoxic effects [18,70]. Although successful in immunosuppressed patients, none"/>
 <result pre="studies [60,71]. Due to the medical importance of HCMV, the" exact="absence of" post="effective ways to prevent infection and the shortcomings of"/>
 <result pre="importance of HCMV, the absence of effective ways to prevent" exact="infection" post="and the shortcomings of existing therapeutic drugs, it is"/>
 <result pre="All approved drugs currently available to prevent or treat HCMV" exact="disease" post="target viral enzymes expressed in the early phase and"/>
 <result pre="drugs currently available to prevent or treat HCMV disease target" exact="viral" post="enzymes expressed in the early phase and critical for"/>
 <result pre="the early phase and critical for late processes in the" exact="infection" post="cycle. In contrast, molecular events before the onset of"/>
 <result pre="gene expression and protein function for improved intervention with HCMV" exact="infection" post="and disease. 2. Major IE Gene Expression 2.1. Transcriptional"/>
 <result pre="Control of the Major IE Gene The outcome of HCMV" exact="infection" post="is believed to depend largely on the level and"/>
 <result pre="from the major IE gene [23,72,73]. This is the first" exact="viral" post="gene to be transcribed following initial infection, and likely"/>
 <result pre="latency, in a process that does not require de novo" exact="viral" post="protein synthesis [13,23,74]. Expression of the major IE gene"/>
 <result pre="or activation state of the infected cell. While productive HCMV" exact="infection" post="is linked to activated transcription, viral latency is characterized"/>
 <result pre="cell. While productive HCMV infection is linked to activated transcription," exact="viral" post="latency is characterized by transcriptional repression at this gene."/>
 <result pre="is located in the unique long (UL) segment of the" exact="viral" post="genome, close to the internal repeat elements. The organization"/>
 <result pre="organization of this gene is unusually complex, not just by" exact="viral" post="standards, as multiple promoters and numerous transcripts including both"/>
 <result pre="these promoters appear to have a specific role during latent" exact="infection" post="or reactivation from latency [75,79,84]. However, the combined major"/>
 <result pre="repeat sequences (18-bp, 19-bp and 21-bp), and is required for" exact="viral" post="replication. It may be further divided into proximal and"/>
 <result pre="contributing multiple cis-acting elements to provide efficient MIEP activation and" exact="viral" post="replication. Accordingly, a long list of activating cellular transcription"/>
 <result pre="in the chromatin or &quot;epigenetic&quot; context. The MIEP may undergo" exact="limited" post="DNA methylation, especially in systems for transgene expression, and"/>
 <result pre="transcription are regulated by DNA methylation following HCMV or MCMV" exact="infection" post="[102,103,104]. Nuclear HCMV genomes form nucleosomes, octamers of core"/>
 <result pre="associated with the major IE gene and the levels of" exact="viral" post="gene expression. For example, association of the MIEP with"/>
 <result pre="to high levels of IE (or transgene) transcription and productive" exact="infection" post="or reactivation from latency [72,110,111,112,113,114,115,116,117,118,119,120]. By contrast, the presence"/>
 <result pre="and either latent or the onset (pre-IE phase) of productive" exact="infection" post="[110,111,112,115,116] (Figure 1). In agreement with these observations, histone"/>
 <result pre="nuclear organelles referred to as nuclear domain 10 or promyelocytic" exact="leukaemia" post="(PML) bodies [133,134,135]. While PML bodies may confer transcriptional"/>
 <result pre="a whole, constituents of these organelles including alpha thalassemia/mental retardation" exact="syndrome" post="X-linked protein (ATRX), death domain-associated protein (DAXX), PML protein"/>
 <result pre="whole, constituents of these organelles including alpha thalassemia/mental retardation syndrome" exact="X-linked" post="protein (ATRX), death domain-associated protein (DAXX), PML protein and"/>
 <result pre="activate, rewire or inhibit numerous of these signalling pathways. HCMV" exact="infection" post="triggers both pathways considered to be proviral as well"/>
 <result pre="which activate similar pathways relevant to the IE phase of" exact="infection" post="[145,146,147,148,149]. In particular, epidermal growth factor receptor (EGFR), platelet-derived"/>
 <result pre="to many cellular properties including motility, proliferation and survival [153,154,155]." exact="Transient" post="induction of this pathway triggered by receptor signalling appears"/>
 <result pre="appears to be followed by more sustained activation involving the" exact="viral" post="major IE proteins [156,157,158,159]. Initial PI3K/AKT activation is required"/>
 <result pre="IE proteins [156,157,158,159]. Initial PI3K/AKT activation is required for efficient" exact="viral" post="entry as well as optimal replication in fibroblasts and"/>
 <result pre="of latency in monocytes [156,158,160,161,162,163]. However, at later times during" exact="infection" post="inhibition of EGFR or PI3K seems to favour viral"/>
 <result pre="during infection inhibition of EGFR or PI3K seems to favour" exact="viral" post="replication and reactivation from latency suggesting a negative regulatory"/>
 <result pre="thought to be involved in the IE phase of HCMV" exact="infection" post="include adenosine monophosphate-activated protein kinase (AMPK) [173], hematopoietic cell"/>
 <result pre="[128]. The activation of kinase signalling pathways in the initial" exact="infection" post="phase comes with multiple, mostly beneficial consequences for the"/>
 <result pre="the PI3K/AKT, MAPK and other signalling pathways relevant to HCMV" exact="infection" post="is nuclear factor kappa B (NF-κΒ). Canonical NF-κΒ activation"/>
 <result pre="[177,178]. This first phase of the NF-κΒ response to HCMV" exact="infection" post="may facilitate IE expression via binding sites in the"/>
 <result pre="widely with cell type, virus strain and other conditions of" exact="infection" post="[179,180,181,182]. A second phase of NF-κΒ activation due to"/>
 <result pre="chemokine genes. Some of these genes encode antiviral proteins including" exact="type I" post="IFNs. HCMV gene products including tegument proteins (e.g., pUL35,"/>
 <result pre="Post-Transcriptional and Translational Control of the Major IE Gene The" exact="primary" post="transcript derived from the MIEP is subject to extensive"/>
 <result pre="the IE1 and IE2 mRNAs is subject to control by" exact="viral" post="non-coding RNAs [189,190,191]. For example, the HCMV long non-coding"/>
 <result pre="to these modifications [205,207,208,209,210,211,212,213,214]. While IE1 is a metabolically highly" exact="stable" post="protein with an estimated intracellular half-life between 21 and"/>
 <result pre="Summary Highly complex interactions between a multitude of cellular and" exact="viral" post="components at the level of DNA, chromatin and upstream"/>
 <result pre="subject to post-translational regulation and are thought to activate the" exact="viral" post="replicative cycle during both initial infection and reactivating from"/>
 <result pre="thought to activate the viral replicative cycle during both initial" exact="infection" post="and reactivating from latency. It is therefore believed that"/>
 <result pre="It is therefore believed that the eventual outcome of HCMV" exact="infection" post="depends on the level and timing of IE1 and"/>
 <result pre="and timing of IE1 and IE2 expression. 3. Major IE" exact="Protein" post="Function 3.1. Role in Activation and Repression of Transcription"/>
 <result pre="shown to activate the HCMV MIEP (positive auto-regulation) and various" exact="viral" post="early gene promoters. In addition, IE2 turned out to"/>
 <result pre="II occupancy at the transcription start site. Furthermore, several heterologous" exact="viral" post="promoters as well as cellular promoters proved to be"/>
 <result pre="IE2 on transcription from a broad variety of promoters in" exact="transient" post="transfection assays earned them the title &quot;promiscuous transactivators&quot;. IE2"/>
 <result pre="EGR1, SP1, TAF4, TBP, TFIIB, TFIID). Many key findings from" exact="transient" post="transfection assays about the impact of IE1 and IE2"/>
 <result pre="crs-dependent repression of the MIEP by IE2 and activation of" exact="viral" post="early genes by IE1 and IE2 [9,218,219,220,221]. In contrast,"/>
 <result pre="target genes. This repression was followed by STAT1-dependent activation of" exact="type II" post="IFN-stimulated genes (ISGs), normally induced by IFN-γ, many of"/>
 <result pre="or IFN-β, IE1 was found to inhibit the induction of" exact="type I" post="ISGs by the trimeric complex of STAT1, STAT2 and"/>
 <result pre="overall low nucleosome levels and temporal reorganization of nucleosomes across" exact="viral" post="genomes observed during productive HCMV infection [9,105]. To our"/>
 <result pre="reorganization of nucleosomes across viral genomes observed during productive HCMV" exact="infection" post="[9,105]. To our knowledge, transcriptional regulation via the IE1"/>
 <result pre="from a promoter internal to major IE exon 4, facilitates" exact="viral" post="genome maintenance and replication during HCMV latency via a"/>
 <result pre="binding by IE1x4 resulting in nuclear retention and partitioning of" exact="viral" post="genomes across latently infected dividing cells [75]. Although IE2"/>
 <result pre="variegation 3-9 homolog 1 (SUV39H1) [126]. Accordingly, transcriptional activation of" exact="viral" post="IE and early genes by IE1 correlates with histone"/>
 <result pre="histone deacetylation and methylation [130,131,234]. 3.3. Role in Inhibition of" exact="Intrinsic" post="Immunity Intrinsic or cell-autonomous immunity is considered the first"/>
 <result pre="and methylation [130,131,234]. 3.3. Role in Inhibition of Intrinsic Immunity" exact="Intrinsic" post="or cell-autonomous immunity is considered the first intracellular line"/>
 <result pre="immunity is considered the first intracellular line of defence against" exact="viral" post="attack. Intrinsic immunity confers (partial) resistance to viruses via"/>
 <result pre="considered the first intracellular line of defence against viral attack." exact="Intrinsic" post="immunity confers (partial) resistance to viruses via constitutively produced"/>
 <result pre="(partial) resistance to viruses via constitutively produced cellular inhibitors of" exact="viral" post="replication known as restriction factors [137,235,236]. Consistent with its"/>
 <result pre="very early stages of HCMV infection, IE1, along with several" exact="viral" post="tegument proteins, has been recognized as a viral antagonist"/>
 <result pre="with several viral tegument proteins, has been recognized as a" exact="viral" post="antagonist of cellular intrinsic immunity [10,12,137]. Specifically, IE1 has"/>
 <result pre="of SP100 observed in the late phase of productive HCMV" exact="infection" post="[241,242,244]. The relevance of IE1-mediated SP100 degradation for HCMV"/>
 <result pre="of SUMOylation by IE1 correlates with organelle disruption resulting in" exact="diffuse" post="nuclear distribution of the associated restriction factors [203,249,250,251]. The"/>
 <result pre="extends beyond the mere targeting of individual restriction factors. Despite" exact="limited" post="experimental evidence, PML targeting and disruption of PML bodies"/>
 <result pre="IE1 function and HCMV replication, especially at low multiplicity of" exact="infection" post="[216,252]. Preceding disruption by IE1, IE2 co-localizes with PML"/>
 <result pre="bodies, most likely as a consequence of binding to the" exact="viral" post="genome which also associates with these organelles [251,253,254]. However,"/>
 <result pre="established in several overexpression settings, its true relevance to HCMV" exact="infection" post="remains to be determined. 3.4. Role in Inhibition of"/>
 <result pre="chemokines are important components of our innate immune system, especially" exact="type I," post="II and III IFNs. The synthesis and secretion of"/>
 <result pre="of ISGs many of which encode proteins that interfere with" exact="viral" post="replication at various points. IE1 confers increased type I"/>
 <result pre="interfere with viral replication at various points. IE1 confers increased" exact="type I" post="IFN resistance to HCMV [225]. This phenotype was largely"/>
 <result pre="acids 410–420 in the presumably disordered &quot;acidic domain&quot; of the" exact="viral" post="protein downstream from the central core domain and upstream"/>
 <result pre="reduced sequence-specific DNA binding by ISGF3 and diminished activation of" exact="type I" post="ISGs (e.g., CXCL10, IFIT2, ISG15, MX1) [209,225,226,265,266]. The C-terminal"/>
 <result pre="C-terminal part of IE1 has also been reported to disrupt" exact="type II" post="ISG activation by STAT1 homodimers, although IE1 is not"/>
 <result pre="via STAT heterodimers) [222,225,226,267]. The ability of IE1 to inhibit" exact="type I" post="ISG induction via STAT2 interaction facilitates HCMV replication and"/>
 <result pre="also contribute to the inhibition of ISG induction during HCMV" exact="infection" post="[216,269]. IE2 is not known to interact with STAT"/>
 <result pre="The underlying mechanism appears to involve inhibition of virus- or" exact="tumor" post="necrosis factor alpha-induced binding of NF-κB to the IFN-β"/>
 <result pre="STING, a critical sensor of intracellular DNA and adaptor for" exact="type I" post="IFN signalling. IE2 facilitated the proteasome-dependent degradation of STING"/>
 <result pre="However, IE1 and IE2 may promote inflammation even in the" exact="absence of" post="viral replication [223,276,277,278,279,280,281]. Consistent with this idea, the IE1-specific"/>
 <result pre="and IE2 may promote inflammation even in the absence of" exact="viral" post="replication [223,276,277,278,279,280,281]. Consistent with this idea, the IE1-specific host"/>
 <result pre="IE1 induced phosphorylation, nuclear accumulation and binding of STAT1 to" exact="type II" post="ISG promoters. Moreover, the repression of STAT3- and the"/>
 <result pre="to their complex roles in the immune response to HCMV" exact="infection" post="[283,284,285]. Based on the stimulatory effect IE1 exerts on"/>
 <result pre="assays as well as vaccine candidates [286,287,288]. 3.6. Role in" exact="Viral" post="Replication, Latency and Reactivation Various highly differentiated cell types"/>
 <result pre="Replication, Latency and Reactivation Various highly differentiated cell types including" exact="primary" post="human fibroblasts are susceptible to HCMV infection and permissive"/>
 <result pre="cell types including primary human fibroblasts are susceptible to HCMV" exact="infection" post="and permissive for viral replication. The importance of IE1"/>
 <result pre="human fibroblasts are susceptible to HCMV infection and permissive for" exact="viral" post="replication. The importance of IE1 in the viral productive"/>
 <result pre="permissive for viral replication. The importance of IE1 in the" exact="viral" post="productive cycle was first highlighted by studying laboratory-adapted high"/>
 <result pre="normal at high but profoundly impaired at low multiplicity of" exact="infection" post="[217,219]. The IE1-specific phenotype was eventually attributed to a"/>
 <result pre="IE1-specific phenotype was eventually attributed to a broad reduction in" exact="viral" post="early gene expression and a failure to form replication"/>
 <result pre="essential. In contrast, IE2 is considered to be indispensable for" exact="viral" post="replication at any multiplicity of infection in cultured fibroblasts"/>
 <result pre="to be indispensable for viral replication at any multiplicity of" exact="infection" post="in cultured fibroblasts [220,221,289,290]. While robust expression of the"/>
 <result pre="[75]. Their results suggest that IE1x4 is required for latent" exact="viral" post="genome replication and maintenance involving interactions with the cellular"/>
 <result pre="expression of IE1 and IE2 was sufficient for induction of" exact="viral" post="early gene expression but not for production of infectious"/>
 <result pre="of viral early gene expression but not for production of" exact="infectious" post="virus [129]. Studies in the mouse and rat models"/>
 <result pre="concluded that the IE1 orthologs are not even required for" exact="viral" post="reactivation from latency [291,292,293]. Thus, while IE2 is almost"/>
 <result pre="is almost certainly necessary for HCMV reactivation (being essential for" exact="viral" post="replication) the importance of IE1 in this process remains"/>
 <result pre="process remains ambiguous. 3.7. Summary IE1 and IE2 are nuclear" exact="localized" post="HCMV proteins expressed at the beginning of infection. They"/>
 <result pre="at the beginning of infection. They autoregulate the MIEP, activate" exact="viral" post="early genes and modulate expression of cellular genes many"/>
 <result pre="in the cytokine and chemokine response to infection. Regulation of" exact="viral" post="gene expression by the IE proteins appears to result"/>
 <result pre="and IE2 may contribute to HCMV pathogenesis even in the" exact="absence of" post="viral replication. 4. Case for Antiviral Targeting of Major"/>
 <result pre="may contribute to HCMV pathogenesis even in the absence of" exact="viral" post="replication. 4. Case for Antiviral Targeting of Major IE"/>
 <result pre="Case for Antiviral Targeting of Major IE Gene Expression or" exact="Protein" post="Function Antiviral strategies for HCMV have long relied on"/>
 <result pre="HCMV have long relied on a single molecular target, the" exact="viral" post="DNA polymerase. Even more recently approved antivirals and candidate"/>
 <result pre="approved antivirals and candidate drugs under development are directed at" exact="viral" post="targets involved in late molecular processes of HCMV replication"/>
 <result pre="of HCMV replication including DNA packaging. At this late stage," exact="infection" post="is fully established and adverse immune-related effects including inflammation"/>
 <result pre="rather than cytopathogenic origins have been proposed for some HCMV" exact="disease" post="including pneumonitis in allogeneic transplant recipients [275,276,277]. Similarly, in"/>
 <result pre="models of pneumonitis MCMV replication was not sufficient to cause" exact="disease" post="[276,277,278,279]. Conversely, MCMV caused pneumonitis in the absence of"/>
 <result pre="to cause disease [276,277,278,279]. Conversely, MCMV caused pneumonitis in the" exact="absence of" post="viral replication [280]. Likewise, HCMV retinitis in AIDS patients"/>
 <result pre="disease [276,277,278,279]. Conversely, MCMV caused pneumonitis in the absence of" exact="viral" post="replication [280]. Likewise, HCMV retinitis in AIDS patients was"/>
 <result pre="pneumonitis in the absence of viral replication [280]. Likewise, HCMV" exact="retinitis" post="in AIDS patients was proposed to be partly due"/>
 <result pre="partly due to immunopathogenesis triggered by IE gene expression, as" exact="disease" post="progressed in the absence of replicating virus [281,294]. Along"/>
 <result pre="triggered by IE gene expression, as disease progressed in the" exact="absence of" post="replicating virus [281,294]. Along these lines, the IE1 protein"/>
 <result pre="Targeting the expression or function of IE1/2 would interfere with" exact="infection" post="at a &quot;bright and early&quot; stage before all other"/>
 <result pre="a &quot;bright and early&quot; stage before all other currently approved" exact="systemic" post="drugs. MIEP- or IE1/2-targeted drugs are predicted to prevent"/>
 <result pre="drugs are predicted to prevent or dampen inflammation even before" exact="viral" post="replication commences. Since IE1/2 are also powerful antagonists of"/>
 <result pre="compounds targeting their expression or function are expected to confer" exact="susceptibility to" post="these host responses providing a novel mechanism of action."/>
 <result pre="the IE1/2-targeted drugs exhibit potential for &quot;epigenetic therapy&quot; as both" exact="viral" post="proteins exert their functions in part via histone modifications,"/>
 <result pre="are expected to interfere not only with an ongoing productive" exact="infection" post="but also with early stages of reactivation, since both"/>
 <result pre="IE1/2 function are likely required for this process. Conceivably, even" exact="viral" post="persistence may be inhibited based on the observation that"/>
 <result pre="may be inhibited based on the observation that IE1x4 mediates" exact="viral" post="genome replication and maintenance during latency. Finally, IE1/2-directed drugs"/>
 <result pre="the FDA [299]. It was approved for treatment of HCMV-induced" exact="retinitis" post="in HIV/AIDS patients via local intravitreous injection, and its"/>
 <result pre="[299]. It was approved for treatment of HCMV-induced retinitis in" exact="HIV/AIDS" post="patients via local intravitreous injection, and its clinical effectiveness"/>
 <result pre="no longer marketed, due to a significant decline in HCMV-induced" exact="retinitis" post="cases in HIV/AIDS patients following the successful implementation of"/>
 <result pre="due to a significant decline in HCMV-induced retinitis cases in" exact="HIV/AIDS" post="patients following the successful implementation of antiretroviral therapy and"/>
 <result pre="an M1SG sequence-specific ribozyme by covalently linking it to an" exact="external" post="guide sequence (EGS) that contains nucleotides complementary to the"/>
 <result pre="In addition, IE1/2 siRNA treatment offset some consequences of HCMV" exact="infection" post="for the host cell, by retaining PML body integrity"/>
 <result pre="signalling [310]. Treatment of cells with IE-targeted siRNA after HCMV" exact="infection" post="resulted in a modest antiviral effect; this is a"/>
 <result pre="observation as therapeutic treatment of patients after establishment of HCMV" exact="infection" post="would be an important clinical application [310]. Although RNAi"/>
 <result pre="UL122/123 successfully excised the UL122/123 gene in 90% of all" exact="viral" post="genomes in an HCMV-infected cell population and resulted in"/>
 <result pre="be useful for targeting HCMV in latently infected cells, where" exact="viral" post="gene expression is low or absent and thus mRNA"/>
 <result pre="available for other molecular approaches discussed in this section and" exact="viral" post="proteins (e.g., DNA polymerase) are not available as a"/>
 <result pre="potential targets to lock down IE transcription and hence inhibit" exact="viral" post="replication and reactivation from latency. In addition, viral proteins"/>
 <result pre="hence inhibit viral replication and reactivation from latency. In addition," exact="viral" post="proteins are known to be directly involved in IE"/>
 <result pre="HCMV to activate IE gene expression. However, compounds targeting these" exact="viral" post="proteins are considered beyond the scope of this review,"/>
 <result pre="existing compounds that inhibit cell signalling pathways modulated by HCMV" exact="infection" post="to facilitate MIEP activation and IE gene expression, (ii)"/>
 <result pre="NF-κΒ pathway [319,326,331]. The NF-κΒ pathway is stimulated upon HCMV" exact="infection" post="and activates the MIEP, driving expression of IE proteins"/>
 <result pre="[319,340]. Clinical use of artesunate for management of drug-resistant HCMV" exact="infections" post="in stem cell or solid organ transplant recipients is"/>
 <result pre="the long and safe clinical history of artesunate treatment in" exact="malaria" post="patients [317]. The first use of artesunate in a"/>
 <result pre="mixed success or that artesunate was ineffective in controlling HCMV" exact="infection" post="[343,344,345]. Further studies are required to fully determine the"/>
 <result pre="organ dissemination without adverse effects [329]. 6.3. NF-κΒ Inhibitors HCMV" exact="infection" post="modulates several cell signalling pathways, including the NF-κΒ and"/>
 <result pre="and HCMV-induced host cell inflammatory response without cytotoxicity [350]. HCMV" exact="infection" post="also up-regulates the PI3K/AKT pathway leading to activation of"/>
 <result pre="manner. LY294002, a PI3K inhibitor, significantly reduces HCMV IE1/2 expression," exact="viral" post="DNA replication and viral titers [156,351]. Disruption of the"/>
 <result pre="inhibitor, significantly reduces HCMV IE1/2 expression, viral DNA replication and" exact="viral" post="titers [156,351]. Disruption of the PI3K pathway and subsequent"/>
 <result pre="identified and developed for a wide range of applications particularly" exact="cancer" post="treatment [353], which can potentially be repurposed as anti-HCMV"/>
 <result pre="IE gene expression and interferes with HCMV-mediated inactivation of the" exact="retinoblastoma" post="(Rb) protein, which controls progression through the G1 phase"/>
 <result pre="of a green fluorescent protein (GFP) reporter [354] or late" exact="viral" post="protein pp28 from the HCMV genome [355,356,357]. These screens"/>
 <result pre="to interference with IE expression or protein production without affecting" exact="viral" post="entry. Several c-Jun N-terminal kinase (JNK) inhibitors were identified"/>
 <result pre="for XMD7 compounds is consistent with IE2′s role as a" exact="viral" post="transcriptional activator, but it is not clear why only"/>
 <result pre="marks to promote IE gene expression and hence HCMV productive" exact="infection" post="or reactivation from latency [358]. Histone demethylase inhibitors (e.g.,"/>
 <result pre="repress IE gene expression from the related Herpes simplex virus" exact="type 1" post="(HSV-1), and importantly they have been shown to potently"/>
 <result pre="and importantly they have been shown to potently inhibit HSV-1" exact="infection" post="and reactivation from latency [123,359,360]. These results suggest that"/>
 <result pre="remodeling enzymes may have potential as HCMV inhibitors [358]. 6.6." exact="Cardiac" post="Glycosides Discovery of novel small molecules that inhibit major"/>
 <result pre="compound family have been used clinically for the treatment of" exact="heart" post="conditions such as congestive heart failure, although toxicity and"/>
 <result pre="used clinically for the treatment of heart conditions such as" exact="congestive heart failure," post="although toxicity and dosage issues mean that they are"/>
 <result pre="clinically for the treatment of heart conditions such as congestive" exact="heart" post="failure, although toxicity and dosage issues mean that they"/>
 <result pre="inhibit IE2 mRNA levels but instead inhibits global translation of" exact="viral" post="and host cell proteins [363]. Cellular translation machinery is"/>
 <result pre="protein synthesis, HCMV is unable to compensate for reductions in" exact="viral" post="protein levels, particularly in IE proteins which are required"/>
 <result pre="are thus essential for virus replication [363]. Convallatoxin-induced inhibition of" exact="viral" post="protein translation by methionine transport reduction is not the"/>
 <result pre="a 9600 compound library for inhibitors of early phase HCMV" exact="infection" post="[361]. Two hit compounds arising from the screen, 1-(3,5-dichloro-4-pyridyl)piperidine-4-carboxamide"/>
 <result pre="also identified [373]. All three structurally diverse compounds act after" exact="viral" post="entry but before IE expression, with significantly decreased IE1"/>
 <result pre="and development as potential antivirals. 7. Inhibition of Major IE" exact="Protein" post="Functions 7.1. IE2 Inhibitors Compounds that inhibit IE2 function"/>
 <result pre="[378]. Within this 150-bp segment is the IR-1 signal (8-bp" exact="inverted" post="repeat element 1), a cis-acting sequence with an established"/>
 <result pre="with TBP, known to be involved in IE2-dependent transactivation of" exact="viral" post="promoters have also been discounted as WC5′s target [378]."/>
 <result pre="promoter DNA [378]. In addition to inhibiting IE2 transactivation of" exact="viral" post="promoters, a second mechanism of action by which WC5"/>
 <result pre="IE2′s auto-repression of its own promoter, a function essential for" exact="viral" post="replication. Although WC5 has been demonstrated to inhibit two"/>
 <result pre="has been demonstrated to inhibit two IE2 functions, transactivation of" exact="viral" post="early and late genes and MIEP auto-regulation, the exact"/>
 <result pre="cytotoxicity [374]. WC5 also inhibits MCMV replication, albeit with ~10-fold" exact="lower" post="activity compared to HCMV [376]. Importantly, WC5′s mechanism of"/>
 <result pre="early gene expression [374]. Assay optimization identified conditions using the" exact="stable" post="cell-line that expresses EGFP under the control of the"/>
 <result pre="of these compounds was confirmed to be inhibition of IE2-mediated" exact="viral" post="early gene transactivation and, like with WC5, a minimal"/>
 <result pre="for the switch from the IE to early phase of" exact="viral" post="replication [364]. Despite the lack of a precise mechanism"/>
 <result pre="is already an FDA-approved drug used in the treatment of" exact="hypertension" post="[381]. 7.2. IE1 Inhibitors Identified inhibitors of IE2-dependent transactivation"/>
 <result pre="cell-based screening platform designed to identify compounds that inhibit a" exact="viral" post="IFN antagonist choice [373]. The platform utilizes two reporter"/>
 <result pre="of the IFN-β or an ISRE-containing promoter, respectively. IE1 counteracts" exact="type I" post="IFN signalling by binding directly to STAT2 thereby preventing"/>
 <result pre="identify compounds that specifically target the IFN antagonist function of" exact="Respiratory" post="Syncytial Virus non-structural protein 2 [373]. To the best"/>
 <result pre="vivo and clinical testing of these molecules, which is currently" exact="limited" post="to only a few studies and compounds. A key"/>
 <result pre="reactivation from latency, a property that existing therapies, which target" exact="viral" post="replication, do not achieve. However, testing key compounds for"/>
 <result pre="with improved efficacy. Overall, &quot;bright and early&quot; events in HCMV" exact="infection" post="deserve more attention as a promising antiviral strategy against"/>
 <result pre="single-cell RNA sequencingMBio20189e00013-1810.1128/mBio.00013-1829535194 7.ChengS.CavinessK.BuehlerJ.SmitheyM.Nikolich-ZugichJ.GoodrumF.Transcriptome-wide characterization of human cytomegalovirus in natural" exact="infection" post="and experimental latencyProc. Natl. Acad. Sci. USA2017114E10586E1059510.1073/pnas.171052211429158406 8.BalazsZ.TombaczD.SzucsA.SnyderM.BoldogkoiZ.Dual platform"/>
 <result pre="Immunol.200832513315218637504 15.TorresL.TangQ.Immediate-Early (IE) gene regulation of cytomegalovirus: IE1- and pp71-mediated" exact="viral" post="strategies against cellular defensesVirol. Sin.20142934335210.1007/s12250-014-3532-925501994 16.WhiteE.A.SpectorD.H.Early viral gene expression"/>
 <result pre="IE1- and pp71-mediated viral strategies against cellular defensesVirol. Sin.20142934335210.1007/s12250-014-3532-925501994 16.WhiteE.A.SpectorD.H.Early" exact="viral" post="gene expression and functionHuman Herpesviruses: Biology, Therapy, and ImmunoprophylaxisArvinA.Campadelli-FiumeG.MocarskiE.MooreP.S.RoizmanB.WhitleyR.YamanishiK.Cambridge"/>
 <result pre="Therapy, and ImmunoprophylaxisArvinA.Campadelli-FiumeG.MocarskiE.MooreP.S.RoizmanB.WhitleyR.YamanishiK.Cambridge University PressCambridge, UK2007 21.AndersD.G.KerryJ.A.PariG.S.DNA synthesis and late" exact="viral" post="gene expressionHuman Herpesviruses: Biology, Therapy, and ImmunoprophylaxisArvinA.Campadelli-FiumeG.MocarskiE.MooreP.S.RoizmanB.WhitleyR.YamanishiK.Cambridge University PressCambridge,"/>
 <result pre="receptorsVaccines201977010.3390/vaccines7030070 25.SinzgerC.JahnG.Human cytomegalovirus cell tropism and pathogenesisIntervirology19963930231910.1159/0001505029130041 26.PooleE.ReevesM.SinclairJ.H.The use of" exact="primary" post="human cells (fibroblasts, monocytes, and others) to assess human"/>
 <result pre="transplant recipientsFront. Microbiol.201910118610.3389/fmicb.2019.0118631191499 30.KennesonA.CannonM.J.Review and meta-analysis of the epidemiology of" exact="congenital" post="cytomegalovirus (CMV) infectionRev. Med. Virol.20071725327610.1002/rmv.53517579921 31.DollardS.C.GrosseS.D.RossD.S.New estimates of the"/>
 <result pre="prevalence of neurological and sensory sequelae and mortality associated with" exact="congenital" post="cytomegalovirus infectionRev. Med. Virol.20071735536310.1002/rmv.54417542052 32.MarsicoC.KimberlinD.W.Congenital Cytomegalovirus infection: Advances and"/>
 <result pre="diagnosis, prevention and treatmentItal. J. Pediatr.2017433810.1186/s13052-017-0358-828416012 33.de VriesJ.J.VossenA.C.KroesA.C.van der ZeijstB.A.Implementing" exact="neonatal" post="screening for congenital cytomegalovirus: Addressing the deafness of policy"/>
 <result pre="treatmentItal. J. Pediatr.2017433810.1186/s13052-017-0358-828416012 33.de VriesJ.J.VossenA.C.KroesA.C.van der ZeijstB.A.Implementing neonatal screening for" exact="congenital" post="cytomegalovirus: Addressing the deafness of policy makersRev. Med. Virol.201121546110.1002/rmv.67921246642"/>
 <result pre="VriesJ.J.VossenA.C.KroesA.C.van der ZeijstB.A.Implementing neonatal screening for congenital cytomegalovirus: Addressing the" exact="deafness" post="of policy makersRev. Med. Virol.201121546110.1002/rmv.67921246642 34.ManicklalS.EmeryV.C.LazzarottoT.BoppanaS.B.GuptaR.K.The &quot;silent&quot; global burden"/>
 <result pre="of policy makersRev. Med. Virol.201121546110.1002/rmv.67921246642 34.ManicklalS.EmeryV.C.LazzarottoT.BoppanaS.B.GuptaR.K.The &quot;silent&quot; global burden of" exact="congenital" post="cytomegalovirusClin. Microbiol. Rev.2013268610210.1128/CMR.00062-1223297260 35.CannonM.J.SchmidD.S.HydeT.B.Review of cytomegalovirus seroprevalence and demographic"/>
 <result pre="and safety of oral ganciclovir in the prevention of cytomegalovirus" exact="disease" post="in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study"/>
 <result pre="Study Group [corrected]Lancet19973501729173310.1016/S0140-6736(97)05535-99413463 37.LowanceD.NeumayerH.H.LegendreC.M.SquiffletJ.P.KovarikJ.BrennanP.J.NormanD.MendezR.KeatingM.R.CoggonG.L.et al.Valacyclovir for the prevention of cytomegalovirus" exact="disease" post="after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study"/>
 <result pre="in heart, heart-lung, and lung transplant recipientsTransplant Int.19991225426010.1111/j.1432-2277.1999.tb01210.x 39.BrizicI.LisnicB.BruneW.HengelH.JonjicS.Cytomegalovirus infection:" exact="Mouse" post="modelCurr. Protoc. Immunol.2018e5110.1002/cpim.5130044539 40.ReddehaseM.J.LemmermannN.A.W.Mouse model of cytomegalovirus disease and"/>
 <result pre="39.BrizicI.LisnicB.BruneW.HengelH.JonjicS.Cytomegalovirus infection: Mouse modelCurr. Protoc. Immunol.2018e5110.1002/cpim.5130044539 40.ReddehaseM.J.LemmermannN.A.W.Mouse model of cytomegalovirus" exact="disease" post="and immunotherapy in the immunocompromised host: Predictions for medical"/>
 <result pre="of coverage and accuracyMatern. Child Health J.20141858459110.1007/s10995-013-1275-023620274 42.KimberlinD.W.JesterP.M.SanchezP.J.AhmedA.Arav-BogerR.MichaelsM.G.AshouriN.EnglundJ.A.EstradaB.JacobsR.F.et al.Valganciclovir for" exact="symptomatic" post="congenital cytomegalovirus diseaseN. Engl. J. Med.201537293394310.1056/NEJMoa140459925738669 43.PriceS.M.BonillaE.ZadorP.LevisD.M.KilgoC.L.CannonM.J.Educating women about"/>
 <result pre="coverage and accuracyMatern. Child Health J.20141858459110.1007/s10995-013-1275-023620274 42.KimberlinD.W.JesterP.M.SanchezP.J.AhmedA.Arav-BogerR.MichaelsM.G.AshouriN.EnglundJ.A.EstradaB.JacobsR.F.et al.Valganciclovir for symptomatic" exact="congenital" post="cytomegalovirus diseaseN. Engl. J. Med.201537293394310.1056/NEJMoa140459925738669 43.PriceS.M.BonillaE.ZadorP.LevisD.M.KilgoC.L.CannonM.J.Educating women about congenital"/>
 <result pre="symptomatic congenital cytomegalovirus diseaseN. Engl. J. Med.201537293394310.1056/NEJMoa140459925738669 43.PriceS.M.BonillaE.ZadorP.LevisD.M.KilgoC.L.CannonM.J.Educating women about" exact="congenital" post="cytomegalovirus: Assessment of health education materials through a web-based"/>
 <result pre="Womens Health20141414410.1186/s12905-014-0144-325433837 44.HarrisonG.J.Current controversies in diagnosis, management, and prevention of" exact="congenital" post="cytomegalovirus: Updates for the pediatric practitionerPediatr. Ann.201544e115e12510.3928/00904481-20150512-1125996198 45.NigroG.AdlerS.P.Hyperimmunoglobulin for"/>
 <result pre="Updates for the pediatric practitionerPediatr. Ann.201544e115e12510.3928/00904481-20150512-1125996198 45.NigroG.AdlerS.P.Hyperimmunoglobulin for prevention of" exact="congenital" post="cytomegalovirus diseaseClin. Infect. Dis.201357Suppl. 4S193S19510.1093/cid/cit58624257426 46.BuxmannH.StackelbergO.M.SchlosserR.L.EndersG.GonserM.Meyer-WittkopfM.HamprechtK.EndersM.Use of cytomegalovirus hyperimmunoglobulin"/>
 <result pre="Infect. Dis.201357Suppl. 4S193S19510.1093/cid/cit58624257426 46.BuxmannH.StackelbergO.M.SchlosserR.L.EndersG.GonserM.Meyer-WittkopfM.HamprechtK.EndersM.Use of cytomegalovirus hyperimmunoglobulin for prevention of" exact="congenital" post="cytomegalovirus disease: A retrospective analysisJ. Perinat. Med.20124043944610.1515/jpm-2011-025722752777 47.NigroG.AdlerS.P.La TorreR.BestA.M.Congenital"/>
 <result pre="47.NigroG.AdlerS.P.La TorreR.BestA.M.Congenital Cytomegalovirus Collaborating, G. Passive immunization during pregnancy for" exact="congenital" post="cytomegalovirus infectionN. Engl. J. Med.20053531350136210.1056/NEJMoa04333716192480 48.NigroG.AdlerS.P.ParrutiG.AnceschiM.M.CocliteE.PezoneI.Di RenzoG.C.Immunoglobulin therapy of"/>
 <result pre="cytomegalovirus infectionN. Engl. J. Med.20053531350136210.1056/NEJMoa04333716192480 48.NigroG.AdlerS.P.ParrutiG.AnceschiM.M.CocliteE.PezoneI.Di RenzoG.C.Immunoglobulin therapy of fetal" exact="cytomegalovirus infection" post="occurring in the first half of pregnancy—A case-control study"/>
 <result pre="infectionN. Engl. J. Med.20053531350136210.1056/NEJMoa04333716192480 48.NigroG.AdlerS.P.ParrutiG.AnceschiM.M.CocliteE.PezoneI.Di RenzoG.C.Immunoglobulin therapy of fetal cytomegalovirus" exact="infection" post="occurring in the first half of pregnancy—A case-control study"/>
 <result pre="of the outcome in childrenJ. Infect. Dis.201220521522710.1093/infdis/jir71822140265 49.VisentinS.ManaraR.MilaneseL.Da RoitA.FornerG.SalviatoE.CittonV.MagnoF.M.OrzanE.MorandoC.et al.Early" exact="primary" post="cytomegalovirus infection in pregnancy: Maternal hyperimmunoglobulin therapy improves outcomes"/>
 <result pre="the outcome in childrenJ. Infect. Dis.201220521522710.1093/infdis/jir71822140265 49.VisentinS.ManaraR.MilaneseL.Da RoitA.FornerG.SalviatoE.CittonV.MagnoF.M.OrzanE.MorandoC.et al.Early primary" exact="cytomegalovirus infection" post="in pregnancy: Maternal hyperimmunoglobulin therapy improves outcomes among infants"/>
 <result pre="outcome in childrenJ. Infect. Dis.201220521522710.1093/infdis/jir71822140265 49.VisentinS.ManaraR.MilaneseL.Da RoitA.FornerG.SalviatoE.CittonV.MagnoF.M.OrzanE.MorandoC.et al.Early primary cytomegalovirus" exact="infection" post="in pregnancy: Maternal hyperimmunoglobulin therapy improves outcomes among infants"/>
 <result pre="fifty-year odyssey: Prospects for a cytomegalovirus vaccine in transplant and" exact="congenital" post="infectionExpert Rev. Vaccines20181788991110.1080/14760584.2018.152608530246580 53.PlotkinS.A.BoppanaS.B.Vaccination against the human cytomegalovirusVaccine2019377437744210.1016/j.vaccine.2018.02.08929622379 54.FuT.M.AnZ.WangD.Progress"/>
 <result pre="54.FuT.M.AnZ.WangD.Progress on pursuit of human cytomegalovirus vaccines for prevention of" exact="congenital" post="infection and diseaseVaccine2014322525253310.1016/j.vaccine.2014.03.05724681264 55.WangD.FuT.M.Progress on human cytomegalovirus vaccines for"/>
 <result pre="on pursuit of human cytomegalovirus vaccines for prevention of congenital" exact="infection" post="and diseaseVaccine2014322525253310.1016/j.vaccine.2014.03.05724681264 55.WangD.FuT.M.Progress on human cytomegalovirus vaccines for prevention"/>
 <result pre="and diseaseVaccine2014322525253310.1016/j.vaccine.2014.03.05724681264 55.WangD.FuT.M.Progress on human cytomegalovirus vaccines for prevention of" exact="congenital" post="infection and diseaseCurr. Opin. Virol.20146132310.1016/j.coviro.2014.02.00424632198 56.LiljaA.E.MasonP.W.The next generation recombinant"/>
 <result pre="diseaseVaccine2014322525253310.1016/j.vaccine.2014.03.05724681264 55.WangD.FuT.M.Progress on human cytomegalovirus vaccines for prevention of congenital" exact="infection" post="and diseaseCurr. Opin. Virol.20146132310.1016/j.coviro.2014.02.00424632198 56.LiljaA.E.MasonP.W.The next generation recombinant human"/>
 <result pre="cytomegalovirus vaccine candidates-beyond gBVaccine2012306980699010.1016/j.vaccine.2012.09.05623041121 57.RiddellS.R.GreenbergP.D.T-cell therapy of cytomegalovirus and human" exact="immunodeficiency" post="virus infectionJ. Antimicrob. Chemother.200045Suppl. T3354310.1093/jac/45.suppl_4.35 58.PeggsK.S.VerfuerthS.PizzeyA.KhanN.GuiverM.MossP.A.MackinnonS.Adoptive cellular therapy for"/>
 <result pre="virus infectionJ. Antimicrob. Chemother.200045Suppl. T3354310.1093/jac/45.suppl_4.35 58.PeggsK.S.VerfuerthS.PizzeyA.KhanN.GuiverM.MossP.A.MackinnonS.Adoptive cellular therapy for early" exact="cytomegalovirus infection" post="after allogeneic stem-cell transplantation with virus-specific T-cell linesLancet20033621375137710.1016/S0140-6736(03)14634-X14585640 59.MuiT.S.KappM.EinseleH.GrigoleitG.U.T-cell"/>
 <result pre="infectionJ. Antimicrob. Chemother.200045Suppl. T3354310.1093/jac/45.suppl_4.35 58.PeggsK.S.VerfuerthS.PizzeyA.KhanN.GuiverM.MossP.A.MackinnonS.Adoptive cellular therapy for early cytomegalovirus" exact="infection" post="after allogeneic stem-cell transplantation with virus-specific T-cell linesLancet20033621375137710.1016/S0140-6736(03)14634-X14585640 59.MuiT.S.KappM.EinseleH.GrigoleitG.U.T-cell"/>
 <result pre="66.El HelouG.RazonableR.R.Safety considerations with current and emerging antiviral therapies for" exact="cytomegalovirus infection" post="in transplantationExpert Opin. Drug Saf.2019181017103010.1080/14740338.2019.166278731478398 67.RazonableR.R.Drug-resistant cytomegalovirus: Clinical implications"/>
 <result pre="HelouG.RazonableR.R.Safety considerations with current and emerging antiviral therapies for cytomegalovirus" exact="infection" post="in transplantationExpert Opin. Drug Saf.2019181017103010.1080/14740338.2019.166278731478398 67.RazonableR.R.Drug-resistant cytomegalovirus: Clinical implications"/>
 <result pre="Immunol.201920843143810.1007/s00430-019-00581-130761409 74.StinskiM.F.IsomuraH.Role of the cytomegalovirus major immediate early enhancer in" exact="acute" post="infection and reactivation from latencyMed. Microbiol. Immunol.200819722323110.1007/s00430-007-0069-718097687 75.Tarrant-ElorzaM.RossettoC.C.PariG.S.Maintenance and"/>
 <result pre="74.StinskiM.F.IsomuraH.Role of the cytomegalovirus major immediate early enhancer in acute" exact="infection" post="and reactivation from latencyMed. Microbiol. Immunol.200819722323110.1007/s00430-007-0069-718097687 75.Tarrant-ElorzaM.RossettoC.C.PariG.S.Maintenance and Replication"/>
 <result pre="immediate-early geneMol. Cell. Biol.198991342134510.1128/MCB.9.3.13422542767 88.NelsonJ.A.Reynolds-KohlerC.SmithB.A.Negative and positive regulation by a" exact="short" post="segment in the 5′-flanking region of the human cytomegalovirus"/>
 <result pre="as well as reduced proliferation and invasion in human cytomegalovirusinfected" exact="glioblastoma" post="cellsOncol. Rep.2019412927293610.3892/or.2019.707430896862 103.BoomR.GeelenJ.L.SolC.J.MinnaarR.P.van der NoordaaJ.Resistance to methylation de novo"/>
 <result pre="productively infected human cellsJ. Virol.200882111671118010.1128/JVI.01218-0818786996 106.KnipeD.M.LiebermanP.M.JungJ.U.McBrideA.A.MorrisK.V.OttM.MargolisD.NietoA.NevelsM.ParksR.J.et al.Snapshots: Chromatin control of" exact="viral" post="infectionVirology201343514115610.1016/j.virol.2012.09.02323217624 107.LiuX.F.WangX.YanS.ZhangZ.AbecassisM.HummelM.Epigenetic control of cytomegalovirus latency and reactivationViruses201351325134510.3390/v505132523698401 108.PaulusC.NitzscheA.NevelsM.Chromatinisation"/>
 <result pre="at human cytomegalovirus promoters during replication in fibroblastsJ. Virol.2008829525953610.1128/JVI.00946-0818653451 112.GrovesI.J.ReevesM.B.SinclairJ.H.Lytic" exact="infection" post="of permissive cells with human cytomegalovirus is regulated by"/>
 <result pre="human cytomegalovirus is regulated by an intrinsic ‘pre-immediate-early’ repression of" exact="viral" post="gene expression mediated by histone post-translational modificationJ. Gen. Virol.2009902364237410.1099/vir.0.012526-019515830"/>
 <result pre="histone H3 acetylation at the CMV promoter are predictive of" exact="stable" post="expression in Chinese hamster ovary cellsBiotechnol. Prog.20163277678610.1002/btpr.227127073121 115.IoudinkovaE.ArcangelettiM.C.RynditchA.De ContoF.MottaF.CovanS.PinardiF.RazinS.V.ChezziC.Control"/>
 <result pre="gene expression by differential histone modifications during lytic and latent" exact="infection" post="of a monocytic cell lineGene200638412012810.1016/j.gene.2006.07.02116989963 116.MurphyJ.C.FischleW.VerdinE.SinclairJ.H.Control of cytomegalovirus lytic"/>
 <result pre="acting factors involved in human cytomegalovirus experimental and natural latent" exact="infection" post="of CD14 (+) monocytes and CD34 (+) CellsPLoS Pathog.20139e100336610.1371/journal.ppat.100336623717203"/>
 <result pre="121.AbrahamC.G.KuleszaC.A.Polycomb repressive complex 2 silences human cytomegalovirus transcription in quiescent" exact="infection" post="modelsJ. Virol.201387131931320510.1128/JVI.02420-1324067968 122.TerhuneS.S.MoormanN.J.CristeaI.M.SavarynJ.P.Cuevas-BennettC.RoutM.P.ChaitB.T.ShenkT.Human cytomegalovirus UL29/28 protein interacts with components"/>
 <result pre="Pathog.20106e100096510.1371/journal.ppat.100096520585571 123.LiangY.VogelJ.L.ArbuckleJ.H.RaiG.JadhavA.SimeonovA.MaloneyD.J.KristieT.M.Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus" exact="infection" post="and reactivation from latencySci. Transl. Med.20135167ra16510.1126/scitranslmed.3005145 124.NevelsM.PaulusC.ShenkT.Human cytomegalovirus immediate-early"/>
 <result pre="from latencySci. Transl. Med.20135167ra16510.1126/scitranslmed.3005145 124.NevelsM.PaulusC.ShenkT.Human cytomegalovirus immediate-early 1 protein facilitates" exact="viral" post="replication by antagonizing histone deacetylationProc. Natl. Acad. Sci. USA2004101172341723910.1073/pnas.040793310115572445"/>
 <result pre="the human cytomegalovirus major immediate-early promoter/enhancer at late times of" exact="infection" post="is mediated by the recruitment of chromatin remodeling enzymes"/>
 <result pre="remodeling enzymes by IE86J. Virol.20068099981000910.1128/JVI.01297-0617005678 127.BigleyT.M.ReitsmaJ.M.MirzaS.P.TerhuneS.S.Human cytomegalovirus pUL97 regulates the" exact="viral" post="major immediate early promoter by phosphorylation-mediated disruption of histone"/>
 <result pre="sufficient to induce early gene expression but not production of" exact="infectious" post="virus in undifferentiated promonocytic THP-1 cellsVirology200736317418810.1016/j.virol.2007.01.03617331553 130.ReevesM.B.Chromatin-mediated regulation of"/>
 <result pre="regulation of cytomegalovirus gene expressionVirus Res.201015713414310.1016/j.virusres.2010.09.01920875471 131.NevelsM.NitzscheA.PaulusC.How to control an" exact="infectious" post="bead string: Nucleosome-based regulation and targeting of herpesvirus chromatinRev."/>
 <result pre="is silenced by Daxx-mediated intrinsic immune defense in model latent" exact="infections" post="established in vitroJ. Virol.2007819109912010.1128/JVI.00827-0717596307 133.Lallemand-BreitenbachV.de TheH.PML nuclear bodies: From"/>
 <result pre="host restriction factors of human cytomegalovirus replication and mechanisms of" exact="viral" post="escapeWorld J. Virol.20165879610.5501/wjv.v5.i3.8727563536 137.TavalaiN.StammingerT.Intrinsic cellular defense mechanisms targeting human"/>
 <result pre="cellular defense mechanisms targeting human cytomegalovirusVirus Res.201115712813310.1016/j.virusres.2010.10.00220934469 138.GeoffroyM.C.Chelbi-AlixM.K.Role of promyelocytic" exact="leukemia" post="protein in host antiviral defenseJ. Interferon Cytokine Res.20113114515810.1089/jir.2010.011121198351 139.DunphyG.FlanneryS.M.AlmineJ.F.ConnollyD.J.PaulusC.JonssonK.L.JakobsenM.R.NevelsM.M.BowieA.G.UnterholznerL.Non-canonical"/>
 <result pre="IFI16 and cyclic GMP-AMP synthase possess distinct functions in regulating" exact="viral" post="gene expression, immune defenses, and apoptotic responses during herpesvirus"/>
 <result pre="cytomegalovirus replicationPLoS Pathog.20128e100249810.1371/journal.ppat.100249822291595 143.CristeaI.M.MoormanN.J.TerhuneS.S.CuevasC.D.O’KeefeE.S.RoutM.P.ChaitB.T.ShenkT.Human cytomegalovirus pUL83 stimulates activity of the" exact="viral" post="immediate-early promoter through its interaction with the cellular IFI16"/>
 <result pre="human cytomegalovirus infectionNature200845539139510.1038/nature0720918701889 148.WangD.ShenkT.Human cytomegalovirus virion protein complex required for" exact="epithelial" post="and endothelial cell tropismProc. Natl. Acad. Sci. USA2005102181531815810.1073/pnas.050920110216319222 149.NogalskiM.T.ChanG.C.StevensonE.V.Collins-McMillenD.K.YurochkoA.D.The"/>
 <result pre="gH/gL/UL128-131 complex triggers the specific cellular activation required for efficient" exact="viral" post="internalization into target monocytesPLoS Pathog.20139e100346310.1371/journal.ppat.100346323853586 150.AltmanA.M.MahmudJ.Nikolovska-ColeskaZ.ChanG.HCMV modulation of cellular"/>
 <result pre="the phosphatidylinositol 3-kinase (PI3-K) pathway: Inhibition of PI3-K activity inhibits" exact="viral" post="replication and virus-induced signalingJ. Virol.2001756022603210.1128/JVI.75.13.6022-6032.200111390604 157.YuY.AlwineJ.C.Human cytomegalovirus major immediate-early"/>
 <result pre="cellular kinase AktJ. Virol.2002763731373810.1128/JVI.76.8.3731-3738.200211907212 158.CobbsC.S.SoroceanuL.DenhamS.ZhangW.KrausM.H.Modulation of oncogenic phenotype in human" exact="glioma" post="cells by cytomegalovirus IE1-mediated mitogenicityCancer Res.20086872473010.1158/0008-5472.CAN-07-229118245472 159.KudchodkarS.B.YuY.MaguireT.G.AlwineJ.C.Human cytomegalovirus infection"/>
 <result pre="in human glioma cells by cytomegalovirus IE1-mediated mitogenicityCancer Res.20086872473010.1158/0008-5472.CAN-07-229118245472 159.KudchodkarS.B.YuY.MaguireT.G.AlwineJ.C.Human" exact="cytomegalovirus infection" post="alters the substrate specificities and rapamycin sensitivities of raptor-"/>
 <result pre="human glioma cells by cytomegalovirus IE1-mediated mitogenicityCancer Res.20086872473010.1158/0008-5472.CAN-07-229118245472 159.KudchodkarS.B.YuY.MaguireT.G.AlwineJ.C.Human cytomegalovirus" exact="infection" post="alters the substrate specificities and rapamycin sensitivities of raptor-"/>
 <result pre="Sci. USA2006103141821418710.1073/pnas.060582510316959881 160.McFarlaneS.PrestonC.M.Human cytomegalovirus immediate early gene expression in the" exact="osteosarcoma" post="line U2OS is repressed by the cell protein ATRXVirus"/>
 <result pre="down-regulation of EGR-1 regulates CD34+ hematopoietic progenitor cell proliferation and" exact="viral" post="reactivationPLoS Pathog.201915e100785410.1371/journal.ppat.100785431725809 166.BuehlerJ.ZeltzerS.ReitsmaJ.PetrucelliA.UmashankarM.RakM.ZagalloP.SchroederJ.TerhuneS.GoodrumF.Opposing regulation of the EGF receptor: A"/>
 <result pre="cytomegalovirus reactivation by recruiting MOZ histone acetyltransferase activity to the" exact="viral" post="promoterJ. Biol. Chem.2019294129011291010.1074/jbc.RA119.00966731273084 175.HuttererC.EickhoffJ.MilbradtJ.KornK.ZeittragerI.BahsiH.WagnerS.ZischinskyG.WolfA.DegenhartC.et al.A novel CDK7 inhibitor of"/>
 <result pre="180.SambucettiL.C.CherringtonJ.M.WilkinsonG.W.MocarskiE.S.NF-κB activation of the cytomegalovirus enhancer is mediated by a" exact="viral" post="transactivator and by T cell stimulationEMBO J.198984251425810.1002/j.1460-2075.1989.tb08610.x2556267 181.CherringtonJ.M.MocarskiE.S.Human cytomegalovirus"/>
 <result pre="2 gene regions of human cytomegalovirus at early times after" exact="infection" post="involves posttranscriptional processing eventsJ. Virol.1991652273228210.1128/JVI.65.5.2273-2282.19911850011 189.AbdallaA.E.MahjoobM.O.AbosalifK.O.A.EjazH.AlameenA.A.M.ElsamanT.Human cytomegalovirus-encoded MicroRNAs: A"/>
 <result pre="Genet. Evol.20197810411910.1016/j.meegid.2019.10411931740397 190.DigginsN.L.HancockM.H.HCMV miRNA targets reveal important cellular pathways for" exact="viral" post="replication, latency, and reactivationNoncodin. RNA201842910.3390/ncrna4040029 191.HookL.HancockM.LandaisI.GrabskiR.BrittW.NelsonJ.A.Cytomegalovirus microRNAsCurr. Opin. Virol.20147404610.1016/j.coviro.2014.03.01524769092"/>
 <result pre="Opin. Virol.20147404610.1016/j.coviro.2014.03.01524769092 192.GreyF.MeyersH.WhiteE.A.SpectorD.H.NelsonJ.A human cytomegalovirus-encoded microRNA regulates expression of multiple" exact="viral" post="genes involved in replicationPLoS Pathog.20073e16310.1371/journal.ppat.003016317983268 193.MurphyE.VanicekJ.RobinsH.ShenkT.LevineA.J.Suppression of immediate-early viral"/>
 <result pre="multiple viral genes involved in replicationPLoS Pathog.20073e16310.1371/journal.ppat.003016317983268 193.MurphyE.VanicekJ.RobinsH.ShenkT.LevineA.J.Suppression of immediate-early" exact="viral" post="gene expression by herpesvirus-coded microRNAs: Implications for latencyProc. Natl."/>
 <result pre="USA20081055453545810.1073/pnas.071191010518378902 194.LauB.PooleE.Van DammeE.BunkensL.SowashM.KingH.MurphyE.WillsM.Van LoockM.SinclairJ.Human cytomegalovirus miR-UL112-1 promotes the down-regulation of" exact="viral" post="immediate early-gene expression during latency to prevent T-cell recognition"/>
 <result pre="member PML via coiled-coil interactionsPLoS Pathog.201410e100451210.1371/journal.ppat.100451225412268 197.TengM.W.Bolovan-FrittsC.DarR.D.WomackA.SimpsonM.L.ShenkT.WeinbergerL.S.An endogenous accelerator for" exact="viral" post="gene expression confers a fitness advantageCell20121511569158010.1016/j.cell.2012.11.05123260143 198.StumpJ.D.StichtH.Investigation of the"/>
 <result pre="confers a fitness advantageCell20121511569158010.1016/j.cell.2012.11.05123260143 198.StumpJ.D.StichtH.Investigation of the dynamics of the" exact="viral" post="immediate-early protein 1 in different conformations and oligomerization statesJ."/>
 <result pre="human cytomegalovirus 86-kilodalton immediate-early protein IE2J. Virol.1998725481549210.1128/JVI.72.7.5481-5492.19989621004 202.PajovicS.WongE.L.BlackA.R.AzizkhanJ.C.Identification of a" exact="viral" post="kinase that phosphorylates specific E2Fs and pocket proteinsMol. Cell."/>
 <result pre="the human cytomegalovirus 86-kilodalton major immediate-early protein IE2/IEP86 affects temporal" exact="viral" post="gene expressionJ. Virol.2005791428143710.1128/JVI.79.3.1428-1437.200515650169 208.NevelsM.BruneW.ShenkT.SUMOylation of the human cytomegalovirus 72-kilodalton"/>
 <result pre="protein facilitates expression of the 86-kilodalton IE2 protein and promotes" exact="viral" post="replicationJ. Virol.2004787803781210.1128/JVI.78.14.7803-7812.200415220454 209.HuhY.H.KimY.E.KimE.T.ParkJ.J.SongM.J.ZhuH.HaywardG.S.AhnJ.H.Binding STAT2 by the acidic domain of"/>
 <result pre="STAT2 by the acidic domain of human cytomegalovirus IE1 promotes" exact="viral" post="growth and is negatively regulated by SUMOJ. Virol.200882104441045410.1128/JVI.00833-0818701593 210.HeiderJ.A.YuY.ShenkT.AlwineJ.C.Characterization"/>
 <result pre="SUMO interactions with the major human cytomegalovirus transactivator IE2p86 for" exact="viral" post="infectionJ. Virol.200983128811289410.1128/JVI.01525-0919812159 215.VardiN.ChaturvediS.WeinbergerL.S.Feedback-mediated signal conversion promotes viral fitnessProc. Natl."/>
 <result pre="transactivator IE2p86 for viral infectionJ. Virol.200983128811289410.1128/JVI.01525-0919812159 215.VardiN.ChaturvediS.WeinbergerL.S.Feedback-mediated signal conversion promotes" exact="viral" post="fitnessProc. Natl. Acad. Sci. USA2018115E8803E881010.1073/pnas.180290511530150412 216.SchererM.OttoV.StumpJ.D.KlinglS.MüllerR.ReuterN.MüllerY.A.StichtH.StammingerT.Characterization of recombinant human"/>
 <result pre="human cytomegaloviruses encoding IE1 mutants L174P and 1-382 reveals that" exact="viral" post="targeting of PML bodies perturbs both intrinsic and innate"/>
 <result pre="Sci. USA199693113211132610.1073/pnas.93.21.113218876134 218.GawnJ.M.GreavesR.F.Absence of IE1 p72 protein function during low-multiplicity" exact="infection" post="by human cytomegalovirus results in a broad block to"/>
 <result pre="infection by human cytomegalovirus results in a broad block to" exact="viral" post="delayed-early gene expressionJ. Virol.2002764441445510.1128/JVI.76.9.4441-4455.200211932411 219.GreavesR.F.MocarskiE.S.Defective growth correlates with reduced"/>
 <result pre="expressionJ. Virol.2002764441445510.1128/JVI.76.9.4441-4455.200211932411 219.GreavesR.F.MocarskiE.S.Defective growth correlates with reduced accumulation of a" exact="viral" post="DNA replication protein after low-multiplicity infection by a human"/>
 <result pre="reduced accumulation of a viral DNA replication protein after low-multiplicity" exact="infection" post="by a human cytomegalovirus ie1 mutantJ. Virol.19987236637910.1128/JVI.72.1.366-379.19989420235 220.MarchiniA.LiuH.ZhuH.Human cytomegalovirus"/>
 <result pre="an IFNγ-like responsePLoS Pathog.201612e100574810.1371/journal.ppat.100574827387064 223.KnoblachT.GrandelB.SeilerJ.NevelsM.PaulusC.Human cytomegalovirus IE1 protein elicits a" exact="type II" post="interferon-like host cell response that depends on activated STAT1"/>
 <result pre="STAT3 in the nucleusJ. Virol.201387107631077610.1128/JVI.01197-1323903834 225.PaulusC.KraussS.NevelsM.A human cytomegalovirus antagonist of" exact="type I" post="IFN-dependent signal transducer and activator of transcription signalingProc. Natl."/>
 <result pre="the mechanism through which the human cytomegalovirus pp71 protein stimulates" exact="viral" post="immediate-early gene expressionJ. Virol.2006803863387110.1128/JVI.80.8.3863-3871.200616571803 236.BieniaszP.D.Intrinsic immunity: A front-line defense"/>
 <result pre="immediate-early gene expressionJ. Virol.2006803863387110.1128/JVI.80.8.3863-3871.200616571803 236.BieniaszP.D.Intrinsic immunity: A front-line defense against" exact="viral" post="attackNat. Immunol.200451109111510.1038/ni112515496950 237.TavalaiN.StammingerT.Interplay between herpesvirus infection and host defense"/>
 <result pre="A front-line defense against viral attackNat. Immunol.200451109111510.1038/ni112515496950 237.TavalaiN.StammingerT.Interplay between herpesvirus" exact="infection" post="and host defense by PML nuclear bodiesViruses20091124010.3390/v103124021994592 238.ReevesM.WoodhallD.ComptonT.SinclairJ.Human cytomegalovirus"/>
 <result pre="of guinea pig cytomegalovirus (GPCMV) IE1 and IE2 homologs in" exact="viral" post="replication and IE1-mediated ND10 targetingVirology201750412214010.1016/j.virol.2017.01.02328189970 240.TangQ.MaulG.G.Mouse cytomegalovirus immediate-early protein"/>
 <result pre="binds with host cell repressors to relieve suppressive effects on" exact="viral" post="transcription and replication during lytic infectionJ. Virol.2003771357136710.1128/JVI.77.2.1357-1367.200312502852 241.LiuX.J.YangB.HuangS.N.WuC.C.LiX.J.ChengS.JiangX.HuF.MingY.Z.NevelsM.et al.Human"/>
 <result pre="progenitor cells as a potential E3 ubiquitin ligasePLoS Pathog.201713e100654210.1371/journal.ppat.100654228750047 242.KimY.E.LeeJ.H.KimE.T.ShinH.J.GuS.Y.SeolH.S.LingP.D.LeeC.H.AhnJ.H.Human" exact="cytomegalovirus infection" post="causes degradation of Sp100 proteins that suppress viral gene"/>
 <result pre="cells as a potential E3 ubiquitin ligasePLoS Pathog.201713e100654210.1371/journal.ppat.100654228750047 242.KimY.E.LeeJ.H.KimE.T.ShinH.J.GuS.Y.SeolH.S.LingP.D.LeeC.H.AhnJ.H.Human cytomegalovirus" exact="infection" post="causes degradation of Sp100 proteins that suppress viral gene"/>
 <result pre="242.KimY.E.LeeJ.H.KimE.T.ShinH.J.GuS.Y.SeolH.S.LingP.D.LeeC.H.AhnJ.H.Human cytomegalovirus infection causes degradation of Sp100 proteins that suppress" exact="viral" post="gene expressionJ. Virol.201185119281193710.1128/JVI.00758-1121880768 243.KhanZ.YaiwK.C.WilhelmiV.LamH.RahbarA.StragliottoG.Soderberg-NauclerC.Human cytomegalovirus immediate early proteins promote"/>
 <result pre="accumulation of mono-SUMOylated PML that is protected from degradation by" exact="herpes" post="simplex virus 1 ICP0J. Virol.201892e01452-1810.1128/JVI.01452-1830258013 247.KangH.KimE.T.LeeH.R.ParkJ.J.GoY.Y.ChoiC.Y.AhnJ.H.Inhibition of SUMO-independent PML"/>
 <result pre="nuclear bodies by IE1 correlates with efficient early stages of" exact="viral" post="gene expression and DNA replication in human cytomegalovirus infectionVirology2000274395510.1006/viro.2000.044810936087"/>
 <result pre="infectionVirology2000274395510.1006/viro.2000.044810936087 253.SourvinosG.TavalaiN.BerndtA.SpandidosD.A.StammingerT.Recruitment of human cytomegalovirus immediate-early 2 protein onto parental" exact="viral" post="genomes in association with ND10 in live-infected cellsJ. Virol.200781101231013610.1128/JVI.01009-0717626080"/>
 <result pre="of human cytomegalovirus (HCMV) mediates the apoptotic control in HCMV" exact="retinitis" post="through up-regulation of the cellular FLICE-inhibitory protein expressionJ. Immunol.20061776199620610.4049/jimmunol.177.9.619917056549"/>
 <result pre="cytomegalovirus immediate-early proteins on p53-mediated apoptosis in coronary artery smooth" exact="muscle" post="cellsCirculation1999991656165910.1161/01.CIR.99.13.165610190872 259.BoninL.R.McDougallJ.K.Human cytomegalovirus IE2 86-kilodalton protein binds p53 but"/>
 <result pre="and pathogen recognition receptor signalingViruses20181051410.3390/v10100514 263.DeFilippisV.R.Induction and evasion of the" exact="type I" post="interferon response by cytomegalovirusesAdv. Exp. Med. Biol.200759830932417892221 264.BiolattiM.GugliesiF.Dell’OsteV.LandolfoS.Modulation of"/>
 <result pre="of the human cytomegalovirus immediate early 1 (IE1) protein disrupts" exact="type II" post="inteferon signalingViruses201461502152410.3390/v604150224699362 268.JaworskaJ.GravelA.FlamandL.Divergent susceptibilities of human herpesvirus 6 variants"/>
 <result pre="inteferon signalingViruses201461502152410.3390/v604150224699362 268.JaworskaJ.GravelA.FlamandL.Divergent susceptibilities of human herpesvirus 6 variants to" exact="type I" post="interferonsProc. Natl. Acad. Sci. USA20101078369837410.1073/pnas.090995110720404187 269.KimY.E.AhnJ.H.Positive role of promyelocytic"/>
 <result pre="I interferonsProc. Natl. Acad. Sci. USA20101078369837410.1073/pnas.090995110720404187 269.KimY.E.AhnJ.H.Positive role of promyelocytic" exact="leukemia" post="protein in type I interferon response and its regulation"/>
 <result pre="Acad. Sci. USA20101078369837410.1073/pnas.090995110720404187 269.KimY.E.AhnJ.H.Positive role of promyelocytic leukemia protein in" exact="type I" post="interferon response and its regulation by human cytomegalovirusPLoS Pathog.201511e100478510.1371/journal.ppat.100478525812002"/>
 <result pre="of the AIM2 inflammasomeMBio201910e02510-1810.1128/mBio.02510-1830755509 273.TaylorR.T.BresnahanW.A.Human cytomegalovirus IE86 attenuates virus- and" exact="tumor" post="necrosis factor α-induced NFκB-dependent gene expressionJ. Virol.200680107631077110.1128/JVI.01195-0617041226 274.KimJ.E.KimY.E.StinskiM.F.AhnJ.H.SongY.J.Human cytomegalovirus"/>
 <result pre="inductionFront. Microbiol.20178185410.3389/fmicb.2017.0185429018427 275.BrittW.Manifestations of human cytomegalovirus infection: Proposed mechanisms of" exact="acute" post="and chronic diseaseCurr. Top. Microbiol. Immunol.200832541747018637519 276.ShanleyJ.D.PesantiE.L.NugentK.M.The pathogenesis of"/>
 <result pre="275.BrittW.Manifestations of human cytomegalovirus infection: Proposed mechanisms of acute and" exact="chronic" post="diseaseCurr. Top. Microbiol. Immunol.200832541747018637519 276.ShanleyJ.D.PesantiE.L.NugentK.M.The pathogenesis of pneumonitis due"/>
 <result pre="of pneumonitis due to murine cytomegalovirusJ. Infect. Dis.198214638839610.1093/infdis/146.3.3886286796 277.GrundyJ.E.ShanleyJ.D.GriffithsP.D.Is cytomegalovirus" exact="interstitial pneumonitis" post="in transplant recipients an immunopathological condition?Lancet1987299699910.1016/S0140-6736(87)92560-82889962 278.GrundyJ.E.ShanleyJ.D.ShearerG.M.Augmentation of graft-versus-host"/>
 <result pre="transplant recipients an immunopathological condition?Lancet1987299699910.1016/S0140-6736(87)92560-82889962 278.GrundyJ.E.ShanleyJ.D.ShearerG.M.Augmentation of graft-versus-host reaction by" exact="cytomegalovirus infection" post="resulting in interstitial pneumonitisTransplantation19853954855310.1097/00007890-198505000-000182986327 279.ScholzM.DoerrH.W.CinatlJ.Inhibition of cytomegalovirus immediate early"/>
 <result pre="recipients an immunopathological condition?Lancet1987299699910.1016/S0140-6736(87)92560-82889962 278.GrundyJ.E.ShanleyJ.D.ShearerG.M.Augmentation of graft-versus-host reaction by cytomegalovirus" exact="infection" post="resulting in interstitial pneumonitisTransplantation19853954855310.1097/00007890-198505000-000182986327 279.ScholzM.DoerrH.W.CinatlJ.Inhibition of cytomegalovirus immediate early"/>
 <result pre="in the lungs free of the virusJ. Clin. Investig.1994941019102510.1172/JCI1174158083343 281.JacobsonM.A.ZegansM.PavanP.R.O’DonnellJ.J.SattlerF.RaoN.OwensS.PollardR.Cytomegalovirus" exact="retinitis" post="after initiation of highly active antiretroviral therapyLancet19973491443144510.1016/S0140-6736(96)11431-89164318 282.WuC.-C.JiangX.WangX.-Z.LiuX.-J.LiX.-J.YangB.YeH.-Q.HarwardtT.GanL.JiangM.et al.Human"/>
 <result pre="results in a virus capable of establishing latency, but with" exact="lower" post="levels of acute virus replication and latency that compromise"/>
 <result pre="virus capable of establishing latency, but with lower levels of" exact="acute" post="virus replication and latency that compromise reactivation efficiencyJ. Gen."/>
 <result pre="Chemother.1993371945195410.1128/AAC.37.9.19458239610 296.DetrickB.NagineniC.N.GrilloneL.R.AndersonK.P.HenryS.P.HooksJ.J.Inhibition of human cytomegalovirus replication in a human retinal" exact="epithelial" post="cell model by antisense oligonucleotidesInvestig. Ophthalmol. Vis. Sci.20014216316911133862 297.AndersonK.P.FoxM.C.Brown-DriverV.MartinM.J.AzadR.F.Inhibition"/>
 <result pre="StudyG.Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus" exact="retinitis" post="that has reactivated or is persistently active despite other"/>
 <result pre="clinical trial of intravitreous fomivirsen for treatment of newly diagnosed" exact="peripheral" post="cytomegalovirus retinitis in patients with AIDSAm. J. Ophtalmol.2002133467474 302.JabsD.A.GriffithsP.D.Fomivirsen"/>
 <result pre="of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus" exact="retinitis" post="in patients with AIDSAm. J. Ophtalmol.2002133467474 302.JabsD.A.GriffithsP.D.Fomivirsen for the"/>
 <result pre="human cytomegalovirus mRNA in vitro and are effective in inhibiting" exact="viral" post="gene expression and growth in human cellsJ. Biol. Chem.2003278372653727410.1074/jbc.M30353120012867424"/>
 <result pre="Acad. Sci.201513549811010.1111/nyas.1275525866265 308.DerksenM.MertensV.PruijnG.J.M.RNase P-mediated sequence-specific cleavage of RNA by engineered" exact="external" post="guide sequencesBiomolecules201553029305010.3390/biom504302926569326 309.KilaniA.F.TrangP.JoS.HsuA.KimJ.NepomucenoE.LiouK.LiuF.RNase P ribozymes selected in vitro to"/>
 <result pre="sequencesBiomolecules201553029305010.3390/biom504302926569326 309.KilaniA.F.TrangP.JoS.HsuA.KimJ.NepomucenoE.LiouK.LiuF.RNase P ribozymes selected in vitro to cleave a" exact="viral" post="mRNA effectively inhibit its expression in cell cultureJ. Biol."/>
 <result pre="targeting of human cytomegalovirus immediate-early or early gene products inhibits" exact="viral" post="replication with differential effects on cellular functionsJ. Virol.2012865660567310.1128/JVI.06338-1122438545 311.HamiltonS.T.MilbradtJ.MarschallM.RawlinsonW.D.Human"/>
 <result pre="by small interfering RNAsJ. Gen. Virol.20048517918410.1099/vir.0.19453-014718633 313.BaiZ.Q.LiL.WangB.LiuZ.J.LiuH.Y.JiangG.Y.WangH.T.YanZ.Y.QianD.M.DingS.Y.et al.Inhibition of human" exact="cytomegalovirus infection" post="by IE86-specific short hairpin RNA-mediated RNA interferenceBiosci. Biotechnol. Biochem.2010741368137210.1271/bbb.9096620622455"/>
 <result pre="small interfering RNAsJ. Gen. Virol.20048517918410.1099/vir.0.19453-014718633 313.BaiZ.Q.LiL.WangB.LiuZ.J.LiuH.Y.JiangG.Y.WangH.T.YanZ.Y.QianD.M.DingS.Y.et al.Inhibition of human cytomegalovirus" exact="infection" post="by IE86-specific short hairpin RNA-mediated RNA interferenceBiosci. Biotechnol. Biochem.2010741368137210.1271/bbb.9096620622455"/>
 <result pre="Gen. Virol.20048517918410.1099/vir.0.19453-014718633 313.BaiZ.Q.LiL.WangB.LiuZ.J.LiuH.Y.JiangG.Y.WangH.T.YanZ.Y.QianD.M.DingS.Y.et al.Inhibition of human cytomegalovirus infection by IE86-specific" exact="short" post="hairpin RNA-mediated RNA interferenceBiosci. Biotechnol. Biochem.2010741368137210.1271/bbb.9096620622455 314.GergenJ.CoulonF.CreneguyA.Elain-DuretN.GutierrezA.PinkenburgO.VerhoeyenE.AnegonI.NguyenT.H.HalaryF.A.et al.Multiplex CRISPR/Cas9"/>
 <result pre="al.Multiplex CRISPR/Cas9 system impairs HCMV replication by excising an essential" exact="viral" post="genePLoS ONE201813e019260210.1371/journal.pone.019260229447206 315.ChinW.X.AngS.K.ChuJ.J.Recent advances in therapeutic recruitment of mammalian"/>
 <result pre="ONE201813e019260210.1371/journal.pone.019260229447206 315.ChinW.X.AngS.K.ChuJ.J.Recent advances in therapeutic recruitment of mammalian RNAi and" exact="bacterial" post="CRISPR-Cas DNA interference pathways as emerging antiviral strategiesDrug Discov."/>
 <result pre="322.SchnepfN.CorvoJ.PorsM.J.MazeronM.C.Antiviral activity of ganciclovir and artesunate towards human cytomegalovirus in" exact="astrocytoma" post="cellsAntivir. Res.20118918618810.1016/j.antiviral.2010.12.00221167209 323.MorereL.AndouardD.LabrousseF.SaadeF.CallisteC.A.CotinS.AubardY.RawlinsonW.D.EsclaireF.HantzS.et al.Ex vivo model of congenital cytomegalovirus"/>
 <result pre="cytomegalovirus in astrocytoma cellsAntivir. Res.20118918618810.1016/j.antiviral.2010.12.00221167209 323.MorereL.AndouardD.LabrousseF.SaadeF.CallisteC.A.CotinS.AubardY.RawlinsonW.D.EsclaireF.HantzS.et al.Ex vivo model of" exact="congenital" post="cytomegalovirus infection and new combination therapiesPlacenta201536414710.1016/j.placenta.2014.11.00325479789 324.ReiterC.FröhlichT.GruberL.HuttererC.MarschallM.VoigtlanderC.FriedrichO.KappesB.EfferthT.TsogoevaS.B.Highly potent artemisinin-derived"/>
 <result pre="in astrocytoma cellsAntivir. Res.20118918618810.1016/j.antiviral.2010.12.00221167209 323.MorereL.AndouardD.LabrousseF.SaadeF.CallisteC.A.CotinS.AubardY.RawlinsonW.D.EsclaireF.HantzS.et al.Ex vivo model of congenital" exact="cytomegalovirus infection" post="and new combination therapiesPlacenta201536414710.1016/j.placenta.2014.11.00325479789 324.ReiterC.FröhlichT.GruberL.HuttererC.MarschallM.VoigtlanderC.FriedrichO.KappesB.EfferthT.TsogoevaS.B.Highly potent artemisinin-derived dimers and"/>
 <result pre="astrocytoma cellsAntivir. Res.20118918618810.1016/j.antiviral.2010.12.00221167209 323.MorereL.AndouardD.LabrousseF.SaadeF.CallisteC.A.CotinS.AubardY.RawlinsonW.D.EsclaireF.HantzS.et al.Ex vivo model of congenital cytomegalovirus" exact="infection" post="and new combination therapiesPlacenta201536414710.1016/j.placenta.2014.11.00325479789 324.ReiterC.FröhlichT.GruberL.HuttererC.MarschallM.VoigtlanderC.FriedrichO.KappesB.EfferthT.TsogoevaS.B.Highly potent artemisinin-derived dimers and"/>
 <result pre="Med. Chem.2015235452545810.1016/j.bmc.2015.07.04826260339 325.ReiterC.FröhlichT.ZeinoM.MarschallM.BahsiH.LeidenbergerM.FriedrichO.KappesB.HampelF.EfferthT.et al.New efficient artemisinin derived agents against human" exact="leukemia" post="cells, human cytomegalovirus and plasmodium falciparum: 2nd generation 1,2,4-trioxane-ferrocene"/>
 <result pre="artemisinin with high activities against plasmodium falciparum, human cytomegalovirus, and" exact="leukemia" post="cellsACS Omega201722422243110.1021/acsomega.7b0031030023664 336.Capci KaragozA.ReiterC.SeoE.J.GruberL.HahnF.LeidenbergerM.KleinV.HampelF.FriedrichO.MarschallM.et al.Access to new highly potent"/>
 <result pre="Lett.2018953453910.1021/acsmedchemlett.7b0041229937978 338.DeMerittI.B.PodduturiJ.P.TilleyA.M.NogalskiM.T.YurochkoA.D.Prolonged activation of NF-κB by human cytomegalovirus promotes efficient" exact="viral" post="replication and late gene expressionVirology2006346153110.1016/j.virol.2005.09.06516303162 339.HancockM.H.NelsonJ.A.Modulation of the NFκb"/>
 <result pre="a potent antiviral agent in a patient with late drug-resistant" exact="cytomegalovirus infection" post="after hematopoietic stem cell transplantationClin. Infect. Dis.2008461455145710.1086/58710618419454 343.WolfD.G.ShimoniA.ResnickI.B.StammingerT.NeumannA.U.ChouS.EfferthT.CaplanO.RoseJ.NaglerA.et al.Human"/>
 <result pre="potent antiviral agent in a patient with late drug-resistant cytomegalovirus" exact="infection" post="after hematopoietic stem cell transplantationClin. Infect. Dis.2008461455145710.1086/58710618419454 343.WolfD.G.ShimoniA.ResnickI.B.StammingerT.NeumannA.U.ChouS.EfferthT.CaplanO.RoseJ.NaglerA.et al.Human"/>
 <result pre="and failure of artesunate treatment in five transplant recipients with" exact="disease" post="caused by drug-resistant cytomegalovirusAntivir. Res.2014101576110.1016/j.antiviral.2013.10.01424184983 346.GilmoreT.D.HerscovitchM.Inhibitors of NF-κB signaling:"/>
 <result pre="NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human" exact="acute" post="myeloid leukemia cellsBlood200510580481110.1182/blood-2004-04-146315454494 350.CaposioP.MussoT.LuganiniA.InoueH.GariglioM.LandolfoS.GribaudoG.Targeting the NF-κB pathway through pharmacological"/>
 <result pre="activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute" exact="myeloid leukemia" post="cellsBlood200510580481110.1182/blood-2004-04-146315454494 350.CaposioP.MussoT.LuganiniA.InoueH.GariglioM.LandolfoS.GribaudoG.Targeting the NF-κB pathway through pharmacological inhibition of"/>
 <result pre="via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid" exact="leukemia" post="cellsBlood200510580481110.1182/blood-2004-04-146315454494 350.CaposioP.MussoT.LuganiniA.InoueH.GariglioM.LandolfoS.GribaudoG.Targeting the NF-κB pathway through pharmacological inhibition of"/>
 <result pre="a potent and effective inhibitor of human cytomegalovirus replication in" exact="primary" post="fibroblast cellsArch. Virol.20121571971197410.1007/s00705-012-1379-722711259 353.WuP.NielsenT.E.ClausenM.H.FDA-approved small-molecule kinase inhibitorsTrends Pharmacol. Sci.20153642243910.1016/j.tips.2015.04.00525975227"/>
 <result pre="CREB and histone H3 post-translational modificationJ. Gen. Virol.20179875476810.1099/jgv.0.00071328100301 358.NehmeZ.PasquereauS.HerbeinG.Control of" exact="viral" post="infections by epigenetic-targeted therapyClin. Epigenet.2019115510.1186/s13148-019-0654-930917875 359.LiangY.QuenelleD.VogelJ.L.MascaroC.OrtegaA.KristieT.M.A novel selective LSD1/KDM1A"/>
 <result pre="and histone H3 post-translational modificationJ. Gen. Virol.20179875476810.1099/jgv.0.00071328100301 358.NehmeZ.PasquereauS.HerbeinG.Control of viral" exact="infections" post="by epigenetic-targeted therapyClin. Epigenet.2019115510.1186/s13148-019-0654-930917875 359.LiangY.QuenelleD.VogelJ.L.MascaroC.OrtegaA.KristieT.M.A novel selective LSD1/KDM1A inhibitor"/>
 <result pre="epigenetic-targeted therapyClin. Epigenet.2019115510.1186/s13148-019-0654-930917875 359.LiangY.QuenelleD.VogelJ.L.MascaroC.OrtegaA.KristieT.M.A novel selective LSD1/KDM1A inhibitor epigenetically blocks" exact="herpes" post="simplex virus lytic replication and reactivation from latencyMBio20134e00558-1210.1128/mBio.00558-1223386436 360.RaiG.KawamuraA.TumberA.LiangY.VogelJ.L.ArbuckleJ.H.RoseN.R.DexheimerT.S.FoleyT.L.KingO.N.et"/>
 <result pre="of inhibitors directed against the early steps of the cytomegalovirus" exact="infectious" post="cycleAntivir. Res.2015113496110.1016/j.antiviral.2014.10.01125446405 363.CohenT.WilliamsJ.D.OppermanT.J.SanchezR.LurainN.S.TortorellaD.Convallatoxin-induced reduction of methionine import effectively inhibits"/>
 <result pre="cycleAntivir. Res.2015113496110.1016/j.antiviral.2014.10.01125446405 363.CohenT.WilliamsJ.D.OppermanT.J.SanchezR.LurainN.S.TortorellaD.Convallatoxin-induced reduction of methionine import effectively inhibits human" exact="cytomegalovirus infection" post="and replicationJ. Virol.201690107151072710.1128/JVI.01050-1627654292 364.MercorelliB.LuganiniA.NannettiG.TabarriniO.PaluG.GribaudoG.LoregianA.drug repurposing approach identifies inhibitors of"/>
 <result pre="Res.2015113496110.1016/j.antiviral.2014.10.01125446405 363.CohenT.WilliamsJ.D.OppermanT.J.SanchezR.LurainN.S.TortorellaD.Convallatoxin-induced reduction of methionine import effectively inhibits human cytomegalovirus" exact="infection" post="and replicationJ. Virol.201690107151072710.1128/JVI.01050-1627654292 364.MercorelliB.LuganiniA.NannettiG.TabarriniO.PaluG.GribaudoG.LoregianA.drug repurposing approach identifies inhibitors of"/>
 <result pre="replicationJ. Virol.201690107151072710.1128/JVI.01050-1627654292 364.MercorelliB.LuganiniA.NannettiG.TabarriniO.PaluG.GribaudoG.LoregianA.drug repurposing approach identifies inhibitors of the prototypic" exact="viral" post="transcription factor IE2 that block human cytomegalovirus replicationCell Chem."/>
 <result pre="platform for high throughput identification of compounds that inhibit a" exact="viral" post="interferon antagonist of choiceAntivir. Res.2018150799210.1016/j.antiviral.2017.10.01229037975 374.LoregianA.MercorelliB.MuratoreG.SinigaliaE.PagniS.MassariS.GribaudoG.GattoB.PalumboM.TabarriniO.et al.The 6-aminoquinolone WC5"/>
 <result pre="an early stage by interfering with the transactivating activity of" exact="viral" post="immediate-early 2 proteinAntimicrob. Agents Chemother.2010541930194010.1128/AAC.01730-0920194695 375.StevensM.BalzariniJ.TabarriniO.AndreiG.SnoeckR.CecchettiV.FravoliniA.De ClercqE.PannecouqueC.Cell-dependent interference of"/>
 <result pre="ClercqE.PannecouqueC.Cell-dependent interference of a series of new 6-aminoquinolone derivatives with" exact="viral" post="(HIV/CMV) transactivationJ. Antimicrob. Chemother.20055684785510.1093/jac/dki32816150861 376.MercorelliB.MuratoreG.SinigaliaE.TabarriniO.BiasoloM.A.CecchettiV.PaluG.LoregianA.A 6-aminoquinolone compound, WC5, with"/>
 <result pre="2 (IE2) protein of human cytomegalovirus that are essential for" exact="viral" post="replicationAntimicrob. Agents Chemother.2014586615662610.1128/AAC.03309-1425155603 379.MassariS.MercorelliB.SancinetoL.SabatiniS.CecchettiV.GribaudoG.PaluG.PannecouqueC.LoregianA.TabarriniO.Design, synthesis, and evaluation of WC5"/>
 <result pre="treatmentChemMedChem201381403141410.1002/cmdc.20130010623757191 380.LuganiniA.CaposioP.MondiniM.LandolfoS.GribaudoG.New cell-based indicator assays for the detection of human" exact="cytomegalovirus infection" post="and screening of inhibitors of viral immediate-early 2 protein"/>
 <result pre="380.LuganiniA.CaposioP.MondiniM.LandolfoS.GribaudoG.New cell-based indicator assays for the detection of human cytomegalovirus" exact="infection" post="and screening of inhibitors of viral immediate-early 2 protein"/>
 <result pre="detection of human cytomegalovirus infection and screening of inhibitors of" exact="viral" post="immediate-early 2 protein activityJ. Appl. Microbiol.20081051791180110.1111/j.1365-2672.2008.03927.x19120629 381.MercorelliB.LuganiniA.CelegatoM.PaluG.GribaudoG.LoregianA.Repurposing the clinically"/>
 <result pre="alkaloid berberine inhibits human cytomegalovirus replication by interfering with the" exact="viral" post="Immediate Early-2 (IE2) protein transactivating activityAntivir. Res.2019164526010.1016/j.antiviral.2019.02.00630738836 383.MercorelliB.GribaudoG.PaluG.LoregianA.Approaches for"/>
</results>
